Xeris Biopharma Holdings, Inc.XERSNASDAQ
Loading
XERS Revenue Growth (YoY Quarterly)•+42.78%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+42.78%
+5.7pp
+31.82%
-24.0pp
+146.85%
+146.8pp
+898.99%
+899.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+11.31%
-7.9pp
+20.78%
+1.6pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +35.39% | +47.94% | +48.84% | +37.06% | +42.78% |
| Gross Profit Growth | +48.41% | +48.24% | +51.55% | +55.83% | +31.82% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +146.85% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +898.99% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +7.94% | +8.49% | +5.14% | +19.21% | +11.31% |
| Weighted Average Shares Diluted Growth | +7.94% | +8.49% | +5.14% | +19.21% | +20.78% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -68.58% | +0.00% | +0.00% | +0.00% | +914.84% |
| Free Cash Flow Growth | -71.48% | +0.00% | +0.00% | +0.00% | +1023.08% |
| Receivables Growth | +3.11% | +23.83% | +25.00% | +30.66% | +26.31% |
| Inventory Growth | +24.04% | +28.90% | +56.55% | +49.52% | +42.55% |
| Asset Growth | +0.14% | -6.29% | +0.89% | +15.29% | +18.72% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +18.44% | +0.02% | -4.66% | -85.91% | -86.09% |
| R&D Expense Growth | -4.54% | -0.87% | +39.87% | +27.09% | +29.25% |
| SG&A Expenses Growth | +6.84% | +14.69% | +11.00% | +3.31% | +18.34% |
1 / 4